Edition:
United States

Aduro Biotech Inc (ADRO.OQ)

ADRO.OQ on NASDAQ Stock Exchange Global Select Market

6.05USD
16 Feb 2018
Change (% chg)

-- (--)
Prev Close
$6.05
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
114,254
52-wk High
$14.00
52-wk Low
$5.85

Chart for

About

Aduro Biotech, Inc. is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company's product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes... (more)

Overall

Beta: --
Market Cap(Mil.): $467.69
Shares Outstanding(Mil.): 77.30
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 178.11 17.27
EPS (TTM): -- -- --
ROI: -- -1.15 35.43
ROE: -- -20.84 17.10

BRIEF-Aduro Biotech Announces Management Changes

* ADURO BIOTECH INC - JENNIFER LEW HAS BEEN PROMOTED TO CHIEF FINANCIAL OFFICER

Jan 05 2018

BRIEF-Aduro Biotech Expands Leading Intellectual Property Position In STING Field With Newly Issued Patent

* ADURO BIOTECH EXPANDS LEADING INTELLECTUAL PROPERTY POSITION IN STING FIELD WITH NEWLY ISSUED PATENT Source text for Eikon: Further company coverage:

Dec 20 2017

BRIEF-Aduro Biotech Provides Update On CRS-207 Programs

* COMPANY HAS DETERMINED THAT IT WILL NOT CONTINUE ADVANCEMENT OF CRS-207

Dec 12 2017

BRIEF-Aduro Biotech ‍announces data from preclinical studies with ADU-1604

* Aduro Biotech Inc - ‍announced data from preclinical studies with ADU-1604, company's humanized anti-CTLA-4 monoclonal antibody​

Nov 10 2017

BRIEF-Aduro Biotech reports Q3 loss per share $0.33

* Q3 earnings per share view $-0.36 -- Thomson Reuters I/B/E/S

Oct 31 2017

BRIEF-Aduro Biotech announces first patient dosed in Phase 1 clinical trial of personalized immunotherapy pLADD

* Aduro Biotech announces first patient dosed in Phase 1 clinical trial of personalized immunotherapy pLADD based on proprietary neoantigen technology

Sep 27 2017

BRIEF-Aduro Biotech announces advancement of adu-s100 into global combination trial with pdr001 for the treatment of solid tumors and lymphomas

* Aduro Biotech announces advancement of ADU-S100 into global combination trial with PDR001 for the treatment of solid tumors and lymphomas

Sep 26 2017

Earnings vs. Estimates